Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Verzistobart · INCAGN-02390, AGEN-2390

Monoclonal antibody · Inhibitor of T-cell immunoglobulin and mucin domain-containing protein 3 (HAVCR2) · developed by Incyte

Phase 2 Most advanced trial (none active)
INCY Developer

What is Verzistobart?

Verzistobart is a fully human Fc-engineered IgG1 kappa antibody that binds TIM-3 on certain T cells, blocking its engagement by phosphatidylserine and galectin-9. It also triggers TIM-3 receptor internalization. It is being studied in head and neck cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
INCAGN-02390, AGEN-2390
Drug type
Monoclonal antibody
Targets
T-cell immunoglobulin and mucin domain-containing protein 3 (HAVCR2)
Mechanism
Inhibitor of T-cell immunoglobulin and mucin domain-containing protein 3 (HAVCR2)
Pathways
T-cell inhibition, tumor cell lysis by cytotoxic T cells
Therapy area
Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
KAC8QY6TMN

Conditions studied

Head and Neck Cancer

Other drugs acting on HAVCR2

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind Verzistobart

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.